-DOCSTART- O


,	O
Kyunggi-do	O
,	O
Korea	O
)	O
and	O
the	O
SNAP	B-BRAND
Kombi	I-BRAND
Plus	I-BRAND
FeLV	I-BRAND
Antigen/FIV	I-BRAND
Antibody	B-DEV
Test	I-DEV
(	O
IDEXX	B-COM
GmbH	I-COM
,	O
Ludwigsburg	O
,	O
Germany	O
)	O
,	O
according	O
to	O
manufacturers	O
'	O
instructions	O
.	O

Transfection	O
was	O
carried	O
out	O
using	O
PolyMAG	B-BRAND
according	O
to	O
the	O
instructions	O
of	O
the	O
manufacturer	O
(	O
Chemicell	B-COM
GmBH	I-COM
,	O
Germany	O
)	O
.	O

Cell	O
culture	O
and	O
adipogenic	O
differentiation	O
3T3-L1	O
(	O
American	B-COM
Type	I-COM
Culture	I-COM
Collection	I-COM
,	O
catalog	O
no	O
.	O

Plasma	O
glucose	O
concentration	O
was	O
measured	O
by	O
the	O
enzymatic	O
hexokinase	O
method	O
using	O
the	O
automatic	B-DEV
analyzer	I-DEV
Konelab	B-BRAND
60	I-BRAND
(	O
Thermo	B-COM
Clinical	I-COM
Labsystem	I-COM
Oy	I-COM
,	O
Espoo	O
,	O
Finland	O
)	O
.	O

C-peptide	O
and	O
insulin	O
in	O
serum	O
were	O
analyzed	O
by	O
a	O
chemiluminescent	O
immunometric	O
technique	O
using	O
the	O
commercial	O
sets	O
Immulite	B-BRAND
2000	I-BRAND
C-peptide	I-BRAND
and	O
Immulite	B-BRAND
2000	I-BRAND
insulin	I-BRAND
(	O
DPC	B-COM
,	O
Los	O
Angeles	O
,	O
CA	O
)	O
.	O

It	O
was	O
sliced	O
to	O
a	O
thickness	O
of	O
2-3	O
µm	O
and	O
the	O
slice	O
was	O
further	O
cropped	O
to	O
fit	O
onto	O
an	O
IR	B-BRAND
ZnSe	I-BRAND
window	I-BRAND
(	O
8.0	O
mm	O
diam.	O
,	O
1.0	O
mm	O
thickness	O
,	O
from	O
Crystran	B-COM
LTD.	I-COM
.	I-COM

UK	O
)	O
within	O
a	O
home-designed	O
,	O
sealed	O
sample	O
holder	O
.	O

An	O
optical	O
microscope	O
image	O
of	O
the	O
sample	O
is	O
shown	O
in	O
Figure	O
1a	O
where	O
the	O
intense	O
yellow	O
of	O
the	O
ZnSe	O
window	O
has	O
been	O
digitally	O
reduced	O
.	O

Genital	O
mucosal	O
tissues	O
were	O
cut	O
into	O
small	O
pieces	O
(	O
maximum	O
size	O
of	O
10	O
¥	O
10	O
¥	O
5	O
mm	O
)	O
,	O
and	O
placed	O
in	O
1	O
·	O
2	O
U/ml	O
Dispase	O
II	O
(	O
Boehringer	B-COM
Mannheim	I-COM
,	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
in	O
complete	O
RPMI	O
medium	O
(	O
3	O
ml	O
per	O
piece	O
)	O
.	O

The	O
tissue-dispase	O
II	O
mixture	O
was	O
incubated	O
in	O
a	O
water	B-DEV
bath	I-DEV
shaker	I-DEV
(	O
New	B-COM
Brunswick	I-COM
Scientific	I-COM
,	I-COM
Inc.	I-COM
,	O
Edison	O
,	O
NJ	O
,	O
USA	O
)	O
for	O
2	O
h	O
at	O
37	O
°C	O
and	O
200	O
r.p.m.	O
.	O

,	O
MN	O
,	O
USA	O
;	O
26	O
mm	O
graft	O
;	O
Gelweave	B-BRAND
,	O
Vascutek	B-COM
Ltd.	I-COM
,	O
Inchinnan	O
,	O
Scotland	O
,	O
UK	O
)	O
.	O

The	O
coronary	O
arteries	O
were	O
reattached	O
with	O
a	O
polyester	O
interposition	O
graft	O
(	O
10	O
mm	O
;	O
Gelweave	B-BRAND
,	O
Vascutek	B-COM
Ltd.	I-COM
)	O
.	O

PLPs	O
and	O
target	O
oligonucleotides	O
,	O
listed	O
in	O
Tables	O
2	O
and	O
5	O
,	O
were	O
synthesized	O
by	O
Eurogentec	B-COM
SA	I-COM
(	O
Seraing	O
,	O
Belgium	O
)	O
.	O

Padlock	O
probe	O
design	O
Relevant	O
nucleic	O
acid	O
sequences	O
derived	O
from	O
GenBank	O
and	O
from	O
independent	O
sequencing	O
studies	O
were	O
aligned	O
by	O
using	O
ClustalW	O
,	O
implemented	O
in	O
BioEdit	O
(	O
http://www.mbio.ncsu	O
.	O


For	O
pelleting	O
of	O
MVs	O
,	O
the	O
supernatants	O
were	O
subjected	O
to	O
an	O
ultracentrifuge	B-DEV
(	O
Optima	B-BRAND
LE-80K	I-BRAND
,	O
fixed-angle	O
rotor	O
45Ti	O
,	O
Beckman	B-COM
Coulter	I-COM
GmbH	I-COM
,	O
Krefeld	O
,	O
Germany	O
)	O
and	O
centrifuged	O
at	O
100,000	O
g	O
at	O
4	O
°C	O
for	O
60	O
min	O
.	O

Hardware	O
Experiments	O
were	O
performed	O
on	O
a	O
Varian	B-BRAND
7	I-BRAND
T	I-BRAND
DDR	I-BRAND
system	O
with	O
G	O
max	O
1/4	O
17.5	O
G/cm	O
,	O
S	O
max	O
1/4	O
87.5	O
G/cm/ms	O
,	O
with	O
an	O
actively	O
detuned	O
transmit/surface	O
receive	O
setup	O
consisting	O
of	O
a	O
72	O
mm	O
dual-tuned	O
1	O
H	O
/	O
13	O
C	O
proton/carbon	O
birdcage	O
volume	O
coil	O
with	O
a	O
40	O
mm	O
two-channel	O
13	O
C	O
surface	O
receive	O
array	O
with	O
an	O
integrated	O
preamp	O
(	O
Rapid	B-COM
Biomedical	I-COM
GMBH	I-COM
,	O
Rimpar	O
,	O
Germany	O
)	O
.	O

A	O
home-made	O
combined	O
RF	O
shield	O
and	O
animal	O
handling	O
system	O
was	O
required	O
to	O
ameliorate	O
undesired	O
electrostatic	O
standing	O
wave	O
interactions	O
occurring	O
inside	O
the	O
magnet	O
bore	O
.	O


,	O
2010	O
)	O
at	O
both	O
9	O
and	O
18	O
months	O
of	O
age	O
were	O
selected	O
,	O
and	O
community	O
DNA	O
was	O
extracted	O
on	O
the	O
Maxwell	B-BRAND
®	I-BRAND
16	I-BRAND
system	O
using	O
the	O
Maxwell	B-BRAND
®	I-BRAND
16	I-BRAND
DNA	I-BRAND
Tissue	I-BRAND
DNA	I-BRAND
purification	B-DEV
kit	I-DEV
(	O
Promega	B-COM
Biotech	I-COM
AB	I-COM
,	O
Sweden	O
)	O
.	O

In	O
all	O
cases	O
,	O
the	O
DNA	O
concentrations	O
were	O
determined	O
fluorometrically	O
(	O
Qubit	B-BRAND
®	I-BRAND
dsDNA	I-BRAND
HS	I-BRAND
assay	I-BRAND
;	O
Invitrogen	B-COM
)	O
and	O
adjusted	O
to	O
1	O
ng	O
lL	O
À1	O
prior	O
to	O
use	O
as	O
template	O
in	O
qPCR	O
.	O

Lipoid	B-BRAND
E80	I-BRAND
(	O
egg	O
lecithin	O
,	O
approx.	O
80	O
%	O
phosphatidylcholine	O
(	O
PC	O
)	O
)	O
,	O
Phospholipon	B-BRAND
®	I-BRAND
90H	I-BRAND
(	O
hydrogenated	O
soy	O
lecithin	O
,	O
min	O
.	O

90	O
%	O
PC	O
)	O
,	O
Lipoid	B-BRAND
S100	I-BRAND
(	O
soy	O
lecithin	O
,	O
min	O
.	O

94	O
%	O
PC	O
)	O
,	O
and	O
Soluthin	B-BRAND
®	B-BRAND
S90	I-BRAND
(	O
soy	O
lechitin	O
,	O
min	O
.	O

83	O
%	O
,	O
associated	O
with	O
calcium	O
chloride	O
)	O
were	O
kindly	O
provided	O
by	O
Lipoid	B-COM
GmbH	I-COM
(	O
Ludwigshafen	O
,	O
Germany	O
)	O
.	O

The	O
6	O
pig	O
ears	O
used	O
in	O
drug	O
release	O
experiments	O
and	O
bioadhesion	O
testing	O
were	O
purchased	O
from	O
Nortura	B-COM
AS	I-COM
(	O
Bardufoss	O
,	O
Norway	O
)	O
.	O

DMSO	O
was	O
purchased	O
from	O
Sigma	B-COM
Chemical	I-COM
Company	I-COM
Ltd.	I-COM
(	O
Poole	O
,	O
United	O
Kingdom	O
)	O
.	O


RT112	O
is	O
a	O
human	O
bladder	O
tumor	O
cell	O
line	O
.	O

2T10	O
cell	O
lines	O
were	O
prepared	O
from	O
RT112	O
cells	O
transfected	O
with	O
full	O
cDNA	O
for	O
human	O
TP	O
and	O
characterized	O
by	O
overexpression	O
of	O
the	O
TP	O
level	O
.	O

To	O
determine	O
arterial	O
stiffness	O
,	O
photoplethysmography	O
(	O
Pulse	B-BRAND
Trace	I-BRAND
2000	I-BRAND
,	O
Cardinal	B-COM
Health/Micro	I-COM
Medical	I-COM
Ltd.	I-COM
,	O
United	O
Kingdom	O
)	O
was	O
used	O
.	O

The	O
measured	O
peak-to-peak	O
time	O
was	O
adjusted	O
to	O
the	O
body	O
size	O
to	O
determine	O
the	O
arterial	O
stiffness	O
index	O
.	O

(	O
v	O
)	O
SBP	O
as	O
defined	O
by	O
gold	O
standard	O
(	O
>	O
250	O
PMN/mm	O
3	O
)	O
or	O
positive	O
cultures	O
were	O
associated	O
with	O
systemic	O
signs	O
of	O
inflammation	O
or	O
cytokine	O
release	O
such	O
as	O
an	O
increase	O
in	O
WBC	O
and	O
CRP	O
in	O
the	O
peripheral	O
blood	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
in	O
patients	O
with	O
DNA	O
positivity	O
,	O
and	O
(	O
vi	O
)	O
standard	O
definition	O
of	O
SBP	O
,	O
diagnosed	O
once	O
at	O
admission	O
,	O
is	O
associated	O
with	O
a	O
trend	O
towards	O
reduced	O
survival	O
,	O
whereas	O
detection	O
of	O
DNA	O
using	O
the	O
LightCycler	B-BRAND
SeptiFast	I-BRAND
Kit	I-BRAND
Mgrade	I-BRAND
(	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Grenzach-Wyhlen	O
,	O
Germany	O
)	O
was	O
not	O
.	O

These	O
results	O
contrast	O
with	O
pioneer	O
findings	O
mainly	O
from	O
a	O
Spanish	O
group	O
,	O
which	O
introduced	O
determination	O
of	O
bacterial	O
DNA	O
in	O
ascitic	O
fluid	O
and	O
published	O
some	O
landmark	O
findings	O
,	O
namely	O
that	O
positive	O
bacterial	O
DNA	O
in	O
ascites	O
is	O
associated	O
with	O
increased	O
cytokine	O
liberation	O
and	O
shortened	O
survival	O
-LSB-	O
10,12	O
-RSB-	O
.	O

RNA	O
concentrations	O
and	O
purity	O
from	O
paraffin	O
tissues	O
and	O
cultured	O
cells	O
were	O
measured	O
with	O
a	O
NanoDrop	B-BRAND
device	I-BRAND
(	O
Peqlab	B-COM
Biotechnologie	I-COM
GmbH	I-COM
,	O
Erlangen	O
,	O
Germany	O
)	O
.	O

Complementary	O
DNA	O
was	O
generated	O
by	O
reverse	O
transcription	O
as	O
described	O
previously	O
.	O

The	O
randomisation	O
list	O
was	O
held	O
by	O
staff	O
at	O
the	O
Contract	O
Research	O
Organisation	O
(	O
CRO	O
)	O
Pharmalog	O
Institut	O
f	O
€	O
ur	O
klinische	O
Forschung	O
GmbH	O
,	O
Munich	O
,	O
Germany	O
,	O
which	O
was	O
not	O
involved	O
in	O
the	O
study	O
conduct	O
.	O

Measurement	O
of	O
bacterial	O
growth	O
on	O
prebiotics	O
Fifteen	O
bifidobacterial	O
and	O
10	O
clostridial	O
strains	O
were	O
tested	O
for	O
their	O
growth	O
on	O
the	O
following	O
prebiotics	O
:	O
raffinose	O
,	O
stachyose	O
,	O
lactulose	O
(	O
Sigma-Aldrich	B-COM
,	O
CZ	O
)	O
,	O
inulin	O
(	O
Frutafit	B-BRAND
s	I-BRAND
,	O
Hages	B-COM
,	O
SK	O
)	O
,	O
OF	O
(	O
Raftilose	B-BRAND
s	I-BRAND
P85	I-BRAND
and	O
P95	O
,	O
Orafti	B-COM
,	O
BE	O
)	O
,	O
and	O
galactooligosaccharides	O
(	O
Vivinal	B-BRAND
s	I-BRAND
,	O
obtained	O
via	O
Humana	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O

Overnight	O
cultures	O
of	O
bifidobacteria	O
and	O
clostridia	O
grown	O
in	O
Wilkins-Chalgren	O
broth	O
(	O
Oxoid	B-COM
,	O
UK	O
)	O
were	O
injected	O
(	O
0.3	O
mL	O
)	O
into	O
10	O
mL	O
of	O
basal	O
medium	O
(	O
BM	O
)	O
containing	O
tryptone	O
(	O
10	O
g	O
)	O
,	O
nutrient	O
broth	O
no.	O
2	O
(	O
10	O
g	O
)	O
,	O
tween	O
80	O
(	O
1	O
mL	O
)	O
,	O
L-cysteine	O
hydrochloride	O
(	O
0.5	O
g	O
)	O
,	O
distilled	O
water	O
(	O
1	O
L	O
)	O
,	O
pH	O
1/4	O
7	O
.	O

Ten	O
nonconsecutive	O
random	O
microscopic	O
fields	O
were	O
analyzed	O
per	O
animal	O
on	O
a	O
light	O
DMRBE	B-BRAND
Leica	O
microscope	B-DEV
(	O
Leica	B-COM
Microsystems	I-COM
GmbH	I-COM
,	O
Wetzlar	O
,	O
Germany	O
)	O
,	O
using	O
an	O
Infinity	B-BRAND
1-5c	I-BRAND
camera	B-DEV
(	O
Lumenera	B-COM
Co.	I-COM
,	O
Ottawa	O
,	O
ON	O
,	O
Canada	O
)	O
.	O

A	O
Biotronik	O
stimulator	B-DEV
(	O
UHS	B-BRAND
20	I-BRAND
universal	O
heart	O
stimulator	O
,	O
Biotronik	B-COM
GmbH	I-COM
,	O
Berlin	O
,	O
Germany	O
)	O
was	O
used	O
to	O
deliver	O
constant	O
current	O
rectangular	O
impulses	O
with	O
pulse	O
widths	O
of	O
2	O
ms	O
at	O
twice	O
diastolic	O
threshold	O
.	O

As	O
for	O
the	O
22K-hGH	O
sample	O
,	O
a	O
commercially	O
supplied	O
recombinant	O
one	O
with	O
an	O
authentic	O
amino	O
acid	O
sequence	O
(	O
Genotropin	B-BRAND
,	O
Amersham	B-COM
Pharmacia	I-COM
Biotech	I-COM
,	O
and	O
Upjohn	B-COM
AB	I-COM
,	O
Sweden	O
)	O
was	O
used	O
.	O

IL-3-dependent	O
mouse	O
pro	O
B	O
cell	O
line	O
(	O
Ba/F3	O
)	O
was	O
from	O
the	O
RIKEN	B-COM
Cell	I-COM
Bank	I-COM
(	O
Ibaraki	O
,	O
Japan	O
)	O
.	O


